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Urethral stricture affects 0.9% of men. Initial treatment is urethrotomy. Approximately, half of the 3 
strictures recur within four years. Options for further treatment are repeat urethrotomy or open 4 
urethroplasty.  5 
Objectives 6 
To compare the effectiveness and cost-effectiveness of urethrotomy with open urethroplasty in adult 7 
men with recurrent bulbar urethral stricture. 8 
Design, Setting and Participants  9 
Open label, two-arm, patient randomised controlled trial. UK NHS hospitals were recruited and 10 
randomised 222 men to urethroplasty or urethrotomy.  11 
Interventions 12 
Urethrotomy is a minimally invasive technique whereby the narrowed area is progressively widened 13 
by cutting the scar tissue with a steel blade mounted on a urethroscope. Urethroplasty is a more 14 
invasive surgery to reconstruct the narrowed area. 15 
Main outcome measures 16 
The primary outcome was the profile over 24 months of a patient-reported outcome measure, the 17 
ICIQ voiding symptom score. The main clinical outcome was time until re-intervention. 18 
Results 19 
The primary analysis included 69 (63%) and 90 (81%) of those allocated to urethroplasty and 20 
urethrotomy respectively. The mean difference between urethroplasty and urethrotomy group was -21 
0.36 (95% confidence interval - CI (-1.74 to 1.02)). Fifteen men allocated to urethroplasty needed a 22 
re-intervention compared to 29 allocated to urethrotomy, hazard ratio (95% CI) 0.52 (0.31 to 0.89).  23 
Conclusion 24 
In men with recurrent bulbar urethral stricture both urethroplasty and urethrotomy improved   25 
voiding symptoms. The benefit lasted longer for urethroplasty. 26 
Patient summary 27 
There was uncertainty about the best treatment for men with recurrent bulbar urethral stricture. We 28 
randomised men to receive one of two treatment options: urethrotomy or urethroplasty. At the end 29 
of the study, both treatments resulted in similar and better symptom scores. However, the 30 
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Main Report  1 
Introduction 2 
Registry studies from the United States estimate the prevalence of urethral stricture to be up to 3 
0.9% of adult men (1). The annular urethral scar, which commonly occurs in the bulbar segment of 4 
the urethra, results in difficulty voiding, threatening urinary retention (2). The first occurrence of 5 
urethral stricture is usually treated by a minimally invasive technique whereby the narrowed area is 6 
progressively widened by either cutting the scar tissue with a steel blade mounted on a 7 
urethroscope, so-called endoscopic urethrotomy, or by the use of graduated urethral dilators. An 8 
estimated half of men will suffer a recurrence within 4 years needing further intervention (3). This 9 
can be by an endoscopic technique or by more invasive surgery to reconstruct the narrowed area: 10 
open urethroplasty (4). Hospital activity data suggest that repeated endoscopic urethrotomy is the 11 
most frequently used alternative (5) to treat bulbar stricture recurrence but specialist clinical 12 
guidelines, based on cohort studies identified by systematic review, recommend that open 13 
urethroplasty should be performed (4,6). In this randomised trial, we aimed to clarify which 14 
procedure was best, primarily in providing symptom control but also considering duration of benefit 15 
prior to disease recurrence. 16 
 17 
Methods 18 
Study design 19 
This was an open-label patient-randomised parallel group superiority trial recruiting across 53 20 
National Health Service (NHS) secondary care providers in the United Kingdom (38 recruited at least 21 
one participant). The trial protocol was published and it contains details about the methods (7). 22 
 23 
Participants 24 
Adult men presenting with bulbar urethral stricture disease having previously undergone at least 25 
one surgical intervention for this condition were identified. Exclusion criteria were current perineal 26 
sepsis and/or urethra-cutaneous fistula. Patients were approached and introduced to the study by 27 
clinical staff at site. Those deciding to participate completed written consent forms for the 24-month 28 
trial period.  29 
 30 
Randomisation and masking 31 
Randomisation was performed using a centralised, automated application hosted by the Centre for 32 
Healthcare and Randomised Trials, University of Aberdeen, UK and accessed by telephone or 33 
through the internet. Participants were allocated to urethroplasty or urethrotomy in a 1:1 ratio with 34 
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recruitment site and time since last procedure (< 12 months or ≥ 12 months) as minimisation 1 
covariates. Clinical trial unit staff were masked to allocation, but participants and surgeons could not 2 
be blinded.  3 
 4 
Procedures 5 
Participants were sent the trial questionnaire — which included the patient reported outcome 6 
measure (PROM) — at baseline, pre-intervention, 3, 6, 9, 12 and 24 months post-intervention, at 18 7 
and 24-months post-randomisation and before and after a re-intervention. At the end of the study 8 
(December 2016) we sent the questionnaire to every participant in the trial. At 3, 12 and 24-month 9 
post-intervention research staff at site contacted participants to complete case report forms (CRF) 10 
face-to-face or by telephone, with supplementation by health care record review. Clinical outcomes, 11 
including adverse events, were collected in the CRF. Uroflowmetry was obtained at baseline, 3 and 12 
between 12 and 24 months after surgery.  13 
 14 
Outcomes 15 
The primary outcome was the profile of the urinary voiding symptom score component of the 16 
surgery patient reported outcome measure (PROM) over 24 months following randomisation. The 17 
questionnaire has been validated in this patient group (8). We used the area under the curve to 18 
summarise each participants’ profile. The PROM has six questions about: delay before starting to 19 
urinate, poor strength of urinary stream, having to strain before urinating, intermittent urinary 20 
stream, feeling of incomplete bladder emptying and post-micturition dribbling. Each item scored 21 
from 0 (no symptoms) to 4 (symptoms all of the time) giving a total score of 0 to 24. The PROM was 22 
chosen as OPEN’s primary outcome to ensure a patient centred trial that can inform patient centred 23 
healthcare delivery; symptoms are likely to be the central concern for patients with bulbar urethral 24 
strictures and the reason why they look for treatment. 25 
 26 
Patient-reported secondary outcomes were: a pictorial description of urine stream strength [from 1 27 
(strong stream) to 4 (weak stream)], impact of urinary symptoms on daily activity [scored from 0 28 
(not at all) to 3 (a lot)], overall satisfaction with sexual function [from 1 (very dissatisfied) to 5 (very 29 
satisfied)], health-related quality of life using the EQ-5D-5L questionnaire reported elsewhere (9).  30 
 31 
Secondary clinical outcomes included difference in re-intervention, rate of improvement of urinary 32 
flow rate and any recurrence. We defined re-interventions for bulbar urethral stricture as any 33 
intervention subsequent to the allocated trial procedure (excluding self-dilatation). Maximum 34 
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urinary flow rate (Qmax) was measured by asking each participant to void at least 150 ml of urine into 1 
a commercial, calibrated uroflowmeter available at their treating centre. An increase in Qmax ≥ 10 2 
ml/s compared to baseline was considered as an improvement (10). Recurrence of bulbar stricture 3 
occurred if at least one of the following conditions were met during the 24 months after 4 
randomisation: a re-intervention had occurred or was scheduled; the maximum flow rate had 5 
deteriorated to the pre-intervention value or the voiding score had deteriorated to baseline value.  6 
 7 
Sample size 8 
Sample size details were provided in the trial’s published protocol (7). Three parameters informed a 9 
revised sample size calculation (after poor recruitment was observed): the minimum clinically 10 
important difference (MID) defined as a > 10% difference in effect estimate in the PROM profile; 11 
power to detect any difference set at 90%; and the standard deviation (SD) of the primary outcome 12 
measure. This was calculated from the 220 measurements of post-intervention PROM voiding score 13 
submitted by the first 69 participants scaled from 0 to 1. The observed SD was 0.15 which was 14 
increased to 0.21 to allow for subsequent changes over trial duration. This gave a revised sample size 15 
of 170 men; we aimed to recruit 210 in total to allow for 19% attrition. The trial was also powered to 16 
determine whether the use of urethroplasty would result in a 30% reduction in re-intervention at 24-17 
months relative to urethrotomy. To detect this difference with 90% power 104 men were required. 18 
Statistical significance was defined at the 2-sided 5% level with corresponding 95% confidence 19 
intervals derived.  20 
 21 
Statistical analysis 22 
The statistical analysis plans are available from https://www.abdn.ac.uk/hsru/what-we-do/trials-23 
unit/statistical-analysis-plans-611.php. The PROM profile, calculated by summing its six questions and 24 
using all available measurements (starting a baseline which was measured immediately prior to 25 
randomisation) to then construct the area under the curve using the trapezoid rule, was analysed 26 
using linear regression adjusted for minimisation covariates. 27 
The primary analysis included all participants who had any surgery and completed at least three 28 
voiding scores: one baseline measure, one early measure (up to 12 months after intervention), and 29 
one later measure (18 or 24-months post-randomisation). We analysed as randomised, i.e. 30 
participants were analysed according to their allocated group regardless of the intervention received.   31 
Given the pragmatic nature of the trial we planned sensitivity analysis to account for missing data 32 
and non-compliance. We did a full intention-to-treat analysis using multiple imputation to include all 33 
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randomised participants in the model according to their allocated intervention. We did a modified 1 
intention-to-treat analysis using multiple imputation to include only participants that had surgery in 2 
the model. Both used the same imputation strategy. We explored differences between responders 3 
and non-responders to inform our missing data model. The auxiliary variables included in the 4 
multiple imputation model were either known predictors of the outcome (ie minimisation variables) 5 
or predictors found by calculating their correlation with the outcome in the OPEN dataset (ie with a 6 
correlation coefficient above 0.3). We calculated an area under the curve for each imputation and 7 
combined these using Rubin’s rules under a missing at random assumption (11,12). We also 8 
explored, using pattern mixture models (11), imputation of a range of values estimated from 9 
observed data using different missing not at random scenarios. For those scenarios we assumed 10 
participants with missing data in the urethroplasty arm had a score from 0 to 10 units lower than the 11 
observed values; we then tested the same for those in the urethrotomy arm. We used Stata’s 12 
command rctmiss to implement this. We did a per-protocol analysis including participants who got 13 
the intervention they were allocated to (ie received the treatment as randomised). 14 
 15 
Secondary outcomes were analysed using generalised linear models appropriate for the distribution 16 
of the outcome with adjustment for minimisation and baseline variables as appropriate. We 17 
analysed time to re-intervention using Cox regression (adjusting for minimisation variables and 18 
centre). For this outcome we used the complete observation time available until database closure 19 
(at least 24 months and up to 48 months for some participants). We also analysed multiple re-20 
interventions using the Andersen-Gill model. Time to recurrence was analysed using a Cox regression 21 
adjusting for minimisation variables and centre. 22 
 23 
Subgroup analyses explored the possible modification of treatment effect by including a treatment-24 
by-factor interaction in models. Factors were: time since last procedure (<12 months or >= 12 25 
months) as a global measure of stricture severity, age (≤ 50 years old or >50), stricture length (≤2 cm 26 
or >2 cm) and number of previous interventions (one or more than one). Adverse and serious 27 
adverse events are presented by intervention received. 28 
 29 
Analyses were carried out in StataCorp. 2015. Stata Statistical Software: Release 14. College Station, 30 






A total of 222 men were randomised between 27/02/2013 and 23/12/2015, out of 1,262 identified 1 
by study sites (Figure 1 & Supplementary Table 1). There were two post-randomisation exclusions 2 
because further assessment prior to intervention showed them to have been ineligible. Recorded 3 
patient characteristics were balanced at baseline, including important clinical characteristics such as 4 
length of stricture and number of previous interventions such as previous urethrotomies (Table 1). 5 
Table 2 presents results for the primary and secondary clinical outcomes. In the primary as-6 
randomised analysis we included 69/108 allocated to the urethroplasty group (63% of those 7 
randomised) and 90/112 allocated to urethrotomy (81% of those randomised). Of the 39 8 
participants excluded in the urethroplasty group and the 22 participants excluded in the 9 
urethrotomy group, 15 and 8 respectively had no surgery at all (Supplementary Table 2). 10 
Supplementary Table 3 presents baseline characteristics by randomised arm and inclusion or 11 
exclusion from the primary analysis status. Participants were similar in most characteristics, although 12 
the proportion of participants never using intermittent self-dilatation at baseline was higher for 13 
those that provided the primary outcome compared with those that did not but balanced across 14 
groups. Participants allocated to the urethrotomy arm and excluded from the analysis had a higher 15 
PROM score at baseline than those included in the analysis. 16 
 17 
Primary outcome 18 
The PROM profile mean (SD) over 24 months after randomisation on a scale from 0 (no symptoms) 19 
to 24 (worst symptoms) was 7.4 (3.8) in the urethroplasty group and 7.8 (4.2) in the urethrotomy 20 
group, a mean (95% CI) difference of -0.36 (-1.74 to 1.02; p=0.6). Sensitivity analysis using multiple 21 
imputation (intention-to-treat analysis) gave a mean difference of –0.33 (95% CI –1.74 to 1.09; 22 
p=0.6); the modified intention-to-treat analysis gave a mean difference of -0.52 (95% CI -2.0 to 0.96; 23 
p=0.5). The estimate of the primary outcome was robust to sensitivity analyses using pattern 24 
mixture models for missing data for all but unrealistic, extreme scenarios (Supplemental Figure 1). 25 
There was no evidence of treatment effect heterogeneity by subgroup (Figure 2). 26 
 27 
Secondary patient reported outcomes 28 
The impact of urinary symptoms profile mean (SD) over 24 months for impact of urinary symptoms 29 
was 1.1 (0.8) for the urethroplasty group versus 1.0 (0.7) in the urethrotomy group. The adjusted mean 30 
(95% CI) difference between treatments was 0.06 (-0.19 to 0.30; p = 0.6). The satisfaction with sexual 31 
function profile mean (SD) over 24 months was 2.9 (1.2) in the urethroplasty group versus 2.5 (1.2) in 32 
the urethrotomy group. The adjusted mean (95% CI) difference between treatments was 0.35 (-0.06 33 
to 0.75), p=0.090. 34 
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Re-interventions and other secondary clinical outcomes 1 
In total, 44 participants had at least one re-intervention and there were 52 re-interventions overall. 2 
Between randomisation and end of follow-up (participants were followed up to 4 years), 15 men in 3 
the urethroplasty group required a re-intervention 474 (399-577) days after initial surgery compared 4 
to 29 men allocated to the urethrotomy group 308 (211-448) days after surgery (median 5 
(interquartile range)). The hazard ratio for time until first re-intervention (95% CI) was 0.52 (0.31 to 6 
0.89), p=0.017 representing a 48% lower risk of re-intervention with urethroplasty. Calculation 7 
including multiple re-interventions per participant gave a similar hazard ratio (95% CI) of 0.49 (0.30 8 
to 0.82), p=0.006. A secondary analysis only involving men who underwent the allocated 9 
intervention (per-protocol) showed a hazard ratio (95% CI) for time to re-intervention of 0.28 (0.15 10 
to 0.55), p<0.001 (Figure 3).  11 
 12 
Participants in the urethroplasty group had twice the odds of experiencing an improvement ≥ 10mL/s 13 
in their maximum flow rate at 3 months compared with participants in the urethrotomy group (OR 14 
95% CI 2.1 (1.05,4.12), p=0.035). At 12 or 24 months the 44 participants in the urethroplasty group 15 
had 2.6 times greater odds of experiencing an improvement of ≥ 10mL/s in their maximum flow rate 16 
compared with the 63 participants in the urethrotomy group (OR 95% CI 2.6 (1.1 to 6.1), p=0.024). 17 
 18 
At the end of follow-up, there were 19 recurrences in the urethroplasty group and 39 in the 19 
urethrotomy group (Hazard ratio 0.46 95% CI (0.29 to 0.72), p=0.001).  20 
 21 
Adverse events 22 
There were 88 adverse events reported during trial with 80 participants suffering at least one adverse 23 
event. Out of those: 43 vs 30 suffered one event in the group receiving urethroplasty vs urethrotomy 24 
(treatment received); 6 vs 0 suffered 2 events and 1 vs 0 suffered 3 events during the trial. See Table 25 
3 for more information. 22 serious adverse events were reported during the trial with 2 related to the 26 
trial intervention. During the trial 17 participants were reported to have experienced at least one 27 
serious adverse event (7 vs 10 in the group that received urethroplasty versus urethrotomy 28 
respectively): 14 participants suffered one serious adverse event (6 vs 8); 1 participant had 2 (0 vs 1) 29 
and 2 participants had 3 events (1 vs 1).   30 
 31 
Discussion 32 
The OPEN trial is the first multi-centre randomised controlled trial comparing the effectiveness and 33 
cost-effectiveness (not reported in this paper) of the two choices available for men suffering 34 
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recurrence of bulbar urethral stricture: endoscopic urethrotomy vs urethroplasty.  We found that at 1 
24-months, participants in both groups had similarly improved symptom scores compared to 2 
baseline. Clinical outcomes, including time to re-intervention, and urinary flow rate (the most 3 
frequently used clinical outcome (10)) favoured urethroplasty on average.  These results were 4 
homogeneous across different subgroups.  5 
The OPEN trial design followed best practice for surgical trials in a pragmatic setting: participants 6 
and clinicians could not blinded, but central trial staff entering and analysing results were masked 7 
where possible. Use of a remote computerised randomisation system ensured allocation 8 
concealment. We set the trial in the UK NHS recruiting from both specialist and general units. The 9 
trial’s primary outcome focused on patients’ symptoms since men with recurrent stricture are most 10 
concerned about their poor and prolonged voiding which threatens urinary retention, a problem 11 
they find distressing and which negatively impacts on their lives (13). A further strength of the study 12 
is that both randomised groups were evenly balanced with respect to stricture length, aetiology, 13 
number of prior recurrences and their prior experience of self-dilatation. The outcomes from both 14 
arms ought to be representative of a “typical” patient with a recurrent bulbar stricture with similar 15 
values to recent published cohorts of men undergoing urethroplasty or urethrotomy.  16 
We faced difficulties in recruiting and retaining participants. This could be due to several reasons.  17 
The two treatments are very different in complexity and short-term patient experience; participants 18 
will have had treatment failure to enter the trial.  Furthermore, we embedded qualitative work and 19 
made changes to the design as a result of that (14). To help improve retention, we provided different 20 
communication options, including to complete outcome questionnaires online (used by 30% of 21 
participants). We used automated alerts to monitor and chased overdue outcome data from 22 
participants and sites. Despite these efforts, we could only include 159/220 (72%) participants in the 23 
primary analysis; 69 (63%) allocated to urethroplasty and 90 (81%) allocated to urethrotomy. This is 24 
a common experience in studies of urethroplasty with number of patients attending clinics declining 25 
with time. The reasons for the differential drop-out between randomised arms are unknown, 26 
however they could be related to more participants receiving their allocated treatment in the 27 
urethrotomy arm or the shorter waiting time for that intervention. Due to this observed difference, 28 
an additional statistical analysis plan was prepared by the trial team’s statistical experts not involved 29 
in the data analysis of the trial. We conducted several sensitivity analyses as a result, including 30 
multiple imputation assuming a missing at random mechanism and pattern mixture models 31 
assuming missing not at random. The OPEN trial results were robust to all but unrealistic scenarios.  32 
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The percentage of SAEs was similar in both the urethroplasty and urethrotomy groups (10.9% vs 1 
11.3%). Given the increased complexity of urethroplasty, a greater proportion of SAEs in that group 2 
would have been expected. However, the serious adverse events rate for urethroplasty is similar to 3 
the 30-day complication rate recently reported in the UK national database (15). One possible 4 
explanation is that there were a total of four re-admissions following urethrotomy, typically 5 
performed as a day case, for bleeding and/or retention. 6 
A systematic literature review, including data from trial registries, which was updated just prior to 7 
trial completion did not identify further relevant trials published or in progress to compare with our 8 
design and results. However, clinical guidance suggests that urethroplasty is the better option, but 9 
this advice has been based on low-level published evidence and expert opinion so far. Outcomes for 10 
participants of our randomised trial were similar to data from non-randomised cohorts of patients 11 
undergoing urethroplasty or urethrotomy in Europe and the USA. The proportion of recurrences 12 
following urethrotomy and the improvement in measured low rate found in the urethrotomy group 13 
was also similar to that found in recent published cohorts (2,16) as well as in a previous randomised 14 
controlled trial of internal urethrotomy versus dilation for male urethral stricture disease (17). 15 
 16 
Conclusion 17 
Our study will help clinicians worldwide to provide more accurate information on the comparative 18 
benefit of urethroplasty and urethrotomy for their male patients with recurrent bulbar urethral 19 
stricture. Our study shows that either procedure is likely to improve symptoms from baseline 20 
without risking significant harms and therefore both should be available. The duration of that 21 
benefit is longer with urethroplasty. Patients, informed by their clinician, will need to balance these 22 
factors in the light of their individual circumstances, values and preferences to decide which 23 
procedure to undergo. It appears that urologists are discouraged from referring men to 24 
urethroplasty, if it will mean a travelling time of longer than 45 minutes for the patient (18). In order 25 
to successfully implement urethroplasty in health care systems, there is a need for robust clinical 26 
pathways that ensure specialist services with sufficient resources in terms of theatre time and 27 
ongoing specialist surgeon availability.  It is likely that this will have implications for training needs 28 
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Table 1 - Participant clinical characteristics and reported 
symptoms at baseline (Data are mean (SD), count or median 
(p25 – p75), count for continuous variables . Binary and 






Variable   
   




Length of stricture (cm)  2.0 (1.4); 67 1.7 (1.1); 63 
Duration of disease (years  7.3 (9.7); 78 9.9 (11.7); 80 
Previous interventions (any type)  1.9 (2.0); 108 1.8 (1.7); 112 
Previous dilatation – 0.4 (0.8);80 0.5 (1.8);83 
Previous urethroplasty  0.1 (0.4);76 0.1 (0.3);82 
Previous urethrotomy  1.6 (1.8);106 1.4 (1.0);109 
Time since last intervention    
< 12 months 36 (33.3) 36 (32.1) 
≥ 12 months 72 (66.7) 76 (67.9) 
Predominant site of stricture in bulbar urethra    
Proximal 30 (27.8) 24 (21.4) 
Mid 34 (31.5) 41 (36.6) 
Distal 17 (15.7) 17 (15.2) 
Unknown 6 (5.6) 14 (12.5) 
Missing 21 (19.4) 16 (14.3) 
Cause of stricture    
Unknown 76 (70.4) 81 (72.3) 
Trauma 11 (10.2) 11 (9.8) 
Infection 5 (4.6) 6 (5.4) 
Other 12 (11.1) 7 (6.3) 
Missing 4 (3.7) 7 (6.3) 
Use of intermittent self-dilatation    
Never 60 (55.6) 66 (58.9) 
Previously 25 (23.1) 31 (27.7) 
Currently 23 (21.3) 14 (12.5) 
Missing 0 (0) 1 (0.9) 
Maximum urinary flow rate (mL/s)  10.0 (6.0); 83 9.7 (5.2); 90 
Urethrogram performed  70 (64.8) 62 (55.4) 
Urethroscopy performed  34 (31.5) 42 (37.5) 
PROM   
Total voiding score mean (standard deviation), 0 (no 
symptoms) to 24 (symptoms all the time)  
13.5 (4.5); 104 13.2 (4.7); 109 
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(95% CI)  
p-value 
Patient reported outcomes 
   Mean 
difference 
 
Profile Void score 7.4 (3.8), 69 7.8 (4.2), 90 -0.36 (-1.74 
to 1.02)  
0.6 
Profile impact of urinary 
symptoms 
1.1 (0.8), 69 1.0 (0.7), 90 0.06 (-0.19 to 
0.30) 
0.6 
Profile satisfaction with sexual 
function 




   Odds ratio  
Q max Improved at 12 or 24-mo 
from baseline1 
19% (18/93) 13% (13/104) 2.64 (1.14 to 
6.15) 
0.024 
   Hazard ratio  
Any recurrence 19  39 0.46 (0.29 to 
0.72) 
0.001 
Re-intervention 15 29 0.52 (0.31 to 
0.89) 
0.017 
The effect sizes presented differ by outcome and are all adjusted to minimisation variables; all effect 2 
sizes are urethroplasty vs urethrotomy. 3 






Table 3 Frequency of adverse events by treatment received 
 Urethroplasty (n=82) Urethrotomy (n=115) 
No. of adverse events 
0 32 (39.0) 85 (73.9) 
1 43 (52.4) 30 (26.1) 
2 6 (7.3) 0 (0) 
3 1 (1.2) 0 (0) 
Adverse events during the perio-operative period 
Mouth pain a 12 (14.6) 2 (1.7) 
Wound infection 4 (4.9) 0 (0) 
Bladder 'spasm' requiring 
treatment  
2 (2.4) 1 (0.9) 
Urinary infection  3 (3.7) 0 (0) 
Initial failed trial without 
catheter 
0 (0) 1 (0.9) 
Adverse events during the re-intervention perio-operative period 
Mouth pain 0 (0) 2 (1.7) 
Wound infection 0 (0) 1 (0.9) 
Urinary infection  0 (0) 2 (1.7) 
Urinary retention 0 (0) 1 (0.9) 
Constipation 0 (0) 1 (0.9) 
Adverse events during follow-up 
Erectile dysfunction 4 (4.9) 3 (2.6) 
Mouth pain 4 (4.9) 0 (0) 
UTI 5 (6.1) 6 (5.2) 
Urinary symptom outcome b 7 (8.5) 6 (5.2) 
Wound infection 1 (1.2) 1 (0.9) 
Wound pain 5 (6.1) 1 (0.9) 
Numb testicles 2 (2.4) 0 (0) 
Issues related to climax c 1 (1.2) 0 (0) 
Otherd 1 (1.2) 3 (2.6) 
Erectile dysfunction and 
wound infection 
1 (1.2) 0 (0) 
Erectile dysfunction and 
wound pain 
1 (1.2) 0 (0) 
Wound infection, UTI and 
fistula 
1 (1.2) 0 (0) 
a – 2 people had 2 events of mouth pain  
b- 1 person had 2 new urinary symptoms 
c- 1 person had 2 reports of issues related to climax 




Table 4 Frequency of serious adverse events by treatment received 
 Urethroplasty (n=82) Urethrotomy (n=115) 
No. of serious adverse events   
22 
 
0 75 (91.5) 105 (91.3) 
1 6 (7.3) 8 (7.0) 
2 0 (0) 1 (0.9) 
3 1 (1.2) 1 (0.9) 
Serious adverse events   
Readmission to hospital 0 (0) a 2 (1.7) 
Diverticular perforation 0 (0) 1 (0.9) 
UTI 3 (3.7) 1 (0.9) 
Haematuria 1 (1.2) 1 (0.9) 
New urinary symptom 1 (1.2) 1 (0.9) 
Wound infection 1 (1.2) 1 (0.9) 
Wound pain 1 (1.2) 0 (0) 
Wound infection and fistula 1 (1.2) 0 (0) 
Death 0 (0) b 1 (0.9) 
Otherc 1 (1.2) 3 (2.6) 
a- 1 person had 3 readmissions to the hospital 
b- Event unrelated to the trial intervention. Death by deep vein thrombosis and pulmonary 
embolism 
c- Urethral bleeding following a urethrogram, posterior circulation cerebral infarct, left 












Figure 2 Subgroup analyses for the PROM voiding score area under the curve (calculated by 












Figure 3 Hazard curves for re-intervention by randomised or treatment received group up to 4 
years after initial intervention. Analysis of participants that had surgery according to their 
randomised allocation (as randomised) or restricted to men who underwent procedure allocated 
at randomisation (per-protocol) 
 
 
